University Cancer & Blood Center

Clinical Trials for Biliary Tract Cancer

1403-0002

A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 With BI 754091 (Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors. View details.

CA126-0015

Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors. View details.

Our Affiliations

The Cancer FoundationNCIACHC Accredited

We’re Here to Help! Click Below to Get Started

Contact Us Now